Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
Status:
Completed
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
Not randomized, multicentric, national phase II trial estimating the efficacy of an
intensification protocol in patients with refractory germ cell tumors with relapse and bad
prognosis.
Treatment consists in two Paclitaxel and Ifosfamide intensification cycles followed by three
Carboplatine and Etoposide high dose cycles. The point is the individual Carboplatine
adjustment to take into account inter-individual patients variability.
This adaptation allow to control each patient plasmatic exposition to avoid both inacceptable
toxicities (such as ear toxicity) and a low exposition losing then the benefit of this high
dose protocol.